NCT01242670CompletedPhase 3
A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older
Resilience Government Services, Inc.17 sites in 1 country1,968 target enrollmentStarted: April 1, 2011Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Enrollment
- 1,968
- Locations
- 17
- Primary Endpoint
- Immune response measured by Ross River Vaccine (RRV)-specific neutralizing titer 21 days after the 3rd vaccination as determined by RRV microneutralization (μNT) assay
Study Overview
Brief Summary
The purpose of the study is to verify the safety and adequacy of the immune response produced by a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine and to demonstrate the consistency of manufacture of 3 separate lots of RRV vaccine.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 16 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject is 16 to 59 years of age on the day of screening (for Stratum A only)
- •Subject is 60 years of age or older on the day of screening (for Stratum B only)
- •Subject and, if applicable, subject's parent(s)/legal guardian(s) has (/have) an understanding of the study and its procedures, agree to its provisions, and give written informed consent prior to study entry
- •Subject provides written assent according to his/her age, if applicable
- •Subject is generally healthy as determined by the investigator's clinical judgment based upon medical history and physical examination
- •Subject is physically and mentally capable of participating in the study and following study procedures
- •Subject agrees to keep a daily record of symptoms for the duration of the study
- •If female of childbearing potential - subject has a negative urine pregnancy test result within 24 hours of the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study
Exclusion Criteria
- •Subject has a Body Mass Index > 35.0
- •Subject has an elevated blood pressure at screening of > 159 mmHg systolic and/or > 99 mmHg diastolic while seated and at rest and confirmed by 2 additional measurements taken at least 30 minutes apart (while seated and at rest)
- •Subject has any inherited or acquired immune deficiency
- •Subject has or has a recent history of significant neurological, cardiovascular, respiratory (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •Subject has a history of arthritis (including RRV disease, joint swelling, tenderness, warmth or erythema) on more than one occasion, not related to trauma (including running) or any episode of non-trauma related arthritis within the previous 6 months
- •Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (> 800 μg/day of beclomethasone dipropionate or equivalent), corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
- •Subjects has received any vaccination within 30 days prior to study entry
- •Subject has received a blood transfusion or immunoglobulins within 90 days prior to study entry
- •Subject has donated blood or plasma within 30 days prior to study entry
- •Subject has a history of any vaccine related contraindicating event (eg, anaphylaxis, allergy to components of the test vaccine, other known contraindications)
- •Subject has a dermatologic condition or tattoos which may interfere with injection site reaction rating
- •Subject has participated in another clinical study involving an investigational drug, biological product or device within 30 days prior to enrollment in this study or is scheduled to participate in another clinical study involving an investigational drug, biological or device during the course of this study
- •Subject has functional or surgical asplenia
- •Subject has a known or suspected problem with alcohol or drug abuse
- •Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting this study
- •Subject is pregnant or lactating
Arms & Interventions
Ross River Virus Vaccine
Experimental
Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
Intervention: Ross River Virus Vaccine (Biological)
Outcomes
Primary Outcomes
Immune response measured by Ross River Vaccine (RRV)-specific neutralizing titer 21 days after the 3rd vaccination as determined by RRV microneutralization (μNT) assay
Time Frame: 21 days after 3rd vaccination
Rate of subjects with a RRV-specific neutralizing titer
Time Frame: 21 days after 3rd vaccination
Rate of subjects with a RRV-specific neutralizing titer 21 days after the third vaccination as determined by RRV microneutralization (μNT) assay
Frequency and severity of injection site and systemic reactions within 7 days of any study vaccination
Time Frame: Within 7 days of any study vaccination
Secondary Outcomes
- Rate of subjects with seroconversion (defined as a positive RRV-specific IgG) titer after vaccination(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Immune response measured by RRV-specific IgG titer(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Rate of subjects with seroconversion(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Frequency and severity of any injection site reactions(Within first 21 days following a study vaccination)
- Rate of subjects with a RRV-specific immunoglobulin G (IgG) titer(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Frequency and severity of any adverse event(During entire study period)
- Rate of subjects with a RRV-specific neutralizing titer(21 days after 1st + 2nd vaccination and 180 days after 1st + 3rd vaccination)
- Immune response measured by RRV-specific neutralizing titer(21 days after 1st + 2nd and 180 days after 1st + 3rd vaccination)
- Fold increase of RRV-specific neutralizing titer(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Fold increase of RRV-specific IgG titer(21 days after 1st, 2nd + 3rd vaccination and 180 days after 1st + 3rd vaccination)
- Frequency and severity of any systemic reactions(Within first 21 days of study vaccination)
- Rate of subjects experiencing arthritis associated with one or more of the systemic symptoms consistent with RRV disease(Occurring at least 3 days after vaccination and lasting for more than 3 weeks)
Investigators
Study Sites (17)
Loading locations...
Similar Trials
Enrolling By Invitation
Phase 3
Phase 3 study, to evaluate the safety and immunogenicity of 10 mcg HXP-GPOVac COVID-19 vaccine boost in comparison to a viral vector-based COVID-19 vaccinesHealthy male and female subjectsTCTR20221026004The Government Pharmaceutical Organization4,000
Not yet recruiting
Phase 3
Phase 3 study, to evaluate the safety and immunogenicity of HXP-GPOVac vaccine in comparison to AstraZeneca's AZD1222 COVID-19 vaccineHealthy male and female subjectsTCTR20220120002The Government Pharmaceutical Organization4,000
Completed
Phase 1
Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and AdolescentsInfluenza, AvianNCT01052402Resilience Government Services, Inc.684
Completed
Phase 3
Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk GroupsInfluenzaNCT00711295Resilience Government Services, Inc.3,583
Completed
Phase 3
A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)Hepatitis A Virus InfectionNCT00835380Merck Sharp & Dohme LLC80